Christophe Crochemore

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States

Are you Christophe Crochemore?

Claim your profile

Publications (1)4.28 Total impact

  • Source
    Ana Roscic · Barbara Baldo · Christophe Crochemore · David Marcellin · Paolo Paganetti
    [Show abstract] [Hide abstract]
    ABSTRACT: J. Neurochem. (2011) 119, 398–407. Huntington’s disease is a progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin gene. This expansion produces a mutant form of the huntingtin protein, which contains an elongated polyglutamine stretch at its amino-terminus. Mutant huntingtin may adopt an aberrant, aggregation-prone conformation predicted to start the pathogenic process leading to neuronal dysfunction and cell death. Thus, strategies reducing mutant huntingtin may lead to disease-modifying therapies. We investigated the mechanisms and molecular targets regulating huntingtin degradation in a neuronal cell model. We first found that mutant and wild-type huntingtin displayed strikingly diverse turn-over kinetics and sensitivity to proteasome inhibition. Then, we show that autophagy induction led to accelerate degradation of mutant huntingtin aggregates. In our neuronal cell model, allosteric inhibition of mTORC1 by everolimus, a rapamycin analogue, did not induce autophagy or affect aggregate degradation. In contrast, this occurred in the presence of catalytic inhibitors of both mTOR complexes mTORC1 and mTORC2. Our data demonstrate the existence of an mTOR-dependent but everolimus-independent mechanism regulating autophagy and huntingtin-aggregate degradation in cells of neuronal origin.
    Full-text · Article · Aug 2011 · Journal of Neurochemistry